Twice-yearly lenacapavir for PrEP reduces HIV infections by 96% | Newswise
Twice-yearly injections of the capsid inhibitor drug lenacapavir can prevent the vast majority of HIV infections, according to a Phase 3 clinical trial published Wednesday in the New England Journal of Medicine. HIV pre-exposure prophylaxis (PrEP) has emerged as a crucial tool for fighting the global HIV epidemic, but researchers say daily pill regimens remain an obstacle…